Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.60 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.60 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | PREP | P48147 | 4/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6707831 | 0.91 | CHRM2 (0.51) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL15239944 | 0.86 | CHRM2 (0.60) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL26577089 | 0.83 | CHRM2 (0.57) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL26125418 | 0.83 | CHRM2 (0.57) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL25010681 | 0.83 | CHRM2 (0.75) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL2123260 | 0.83 | CHRM2 (0.75) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL8374380 | 0.82 | CHRM2 (0.64) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL27457738 | 0.82 | CHRM2 (0.64) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL12425806 | 0.82 | CHRM2 (0.64) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL27457736 | 0.82 | CHRM2 (0.64) | CHRM2CHRM1CHRM3HSD11B1PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029570-B1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-10-15 | — | — | EP | disclosed |
| US-8324204-B2 | Fused thiophene derivatives as kinase inhibitors | UCB PHARMA SA (BE) | 2012-12-04 | — | — | US | disclosed |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-12-02 | — | — | US | disclosed |
| US-7012074-B2 | 3,8-Diazabicyclo[3.2.1]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | PIKFYVE, PI4KA, PIK3CA | CHRM2 4785/4885CHRM1 4812/4885CHRM3 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.